Loading...
XNASNDRA
Market cap2mUSD
Dec 24, Last price  
5.36USD
1D
-4.36%
1Q
2,373.72%
IPO
-99.86%
Name

ENDRA Life Sciences Inc

Chart & Performance

D1W1MN
XNAS:NDRA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.03%
Shrs. gr., 5y
109.25%
Rev. gr., 5y
-70.98%
Revenues
0k
559,3551,410,064515,582351,6226,17400000
Net income
-10m
L-23.79%
-2,180,878-2,279,204-2,775,369-5,376,962-9,796,261-15,554,530-11,966,769-11,189,705-13,200,625-10,060,250
CFO
-10m
L-25.22%
-1,397,229-842,727-1,315,623-3,300,914-7,702,481-8,588,851-10,770,595-11,122,384-12,769,371-9,548,775
Earnings
Mar 26, 2025

Profile

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
URL
https://www.endrainc.com/
IPO date
Jun 28, 2017
Employees
21
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
10,796
13,392
11,723
Unusual Expense (Income)
NOPBT
(10,796)
(13,392)
(11,723)
NOPBT Margin
Operating Taxes
22
(42)
Tax Rate
NOPAT
(10,796)
(13,413)
(11,681)
Net income
(10,060)
-23.79%
(13,201)
17.97%
(11,190)
-6.49%
Dividends
(840)
(8)
(121)
Dividend yield
0.00%
0.00%
0.01%
Proceeds from repurchase of equity
6,483
8,400
10,616
BB yield
-0.68%
-1.43%
-0.75%
Debt
Debt current
202
181
132
Long-term debt
558
884
1,197
Deferred revenue
Other long-term liabilities
Net debt
(2,074)
(3,824)
(8,132)
Cash flow
Cash from operating activities
(9,549)
(12,769)
(11,122)
CAPEX
(34)
(203)
(45)
Cash from investing activities
(25)
(203)
(45)
Cash from financing activities
7,518
8,400
13,402
FCF
(8,406)
(14,274)
(13,049)
Balance
Cash
2,834
4,889
9,462
Long term investments
Excess cash
2,834
4,889
9,462
Stockholders' equity
(91,924)
(81,864)
(68,673)
Invested Capital
97,977
89,615
80,136
ROIC
ROCE
EV
Common stock shares outstanding
9,037
2,891
2,046
Price
106.00
-47.91%
203.50
-70.58%
691.80
-7.76%
Market cap
957,930
62.81%
588,378
-58.43%
1,415,516
96.68%
EV
955,856
584,554
1,407,384
EBITDA
(10,521)
(13,158)
(11,498)
EV/EBITDA
Interest
22
Interest/NOPBT